Your Health, We Care
On September 4, 2020, the U.S. Food and Drug Administration (FDA) approved Pralsetinib (trade name: Gavreto) for the treatment of adult patients with metastatic RET gene fusion-positive non-small cell lung cancer.
On December 1, 2020, Genentech announced that the U.S. Food and Drug Administration (FDA) had approved Pralsetinib (trade name: Gavreto) for the treatment of patients with advanced or metastatic RET gene mutation-positive and RET gene fusion-positive thyroid cancer.
On August 9, 2023, the U.S. Food and Drug Administration (FDA) approved Pralsetinib (trade name: Gavreto) for the routine treatment of RET gene fusion-positive non-small cell lung cancer.
On December 1, 2020, South San Francisco, California – Genentech, a member of th···【more】
Release date：2026-01-15Recommended：61
On August 9, 2023, the U.S. Food and Drug Administration (FDA) approved pralseti···【more】
Release date：2026-01-15Recommended：49
